NCT01006018

DPP-4 Inhibition and TZD for DM Prevention

DPP-4 Inhibition and Thiazolidinedione for Diabetes Mellitus Prevention (DInT DM Study)

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: Emory University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

To determine whether treatment with the diabetes medication, Januvia (sitagliptin), with or without another diabetes medicine, Actos (pioglitazone), will improve insulin secretion and insulin response individuals with Impaired Glucose Tolerance (IGT), a form of prediabetes.

Conditions

• Prediabetic State

Interventions

Type	Name	Description
DRUG	Sitagliptin + Pioglitazone PLACEBO	Sitagliptin 100 mg tablet daily + Pioglitazone PLACEBO 15 mg capsule daily
DRUG	Sitagliptin + Pioglitazone	Sitagliptin 100 mg tablet daily + Pioglitazone 15 mg capsule daily
DRUG	PLACEBO	Sitagliptin placebo 100 mg tablet daily + Pioglitazone placebo 15 mg capsule daily

Timeline

• Start date: 2011-07-01
• Primary completion: 2011-12-01
• Completion: 2011-12-01
• First posted: 2009-11-02
• Last updated: 2013-12-05
• Results posted: 2013-06-07

Locations

2 sites across 1 country: United States